Zevra Therapeutics

Today we announced that our company will acquire Acer Therapeutics Inc., effectively expanding our rare disease portfolio and accelerating our growth into a commercial company. The acquisition brings us unique rare disease commercial capabilities that will support our existing pipeline as it advances. We are encouraged by the strength of Acer’s portfolio of rare programs and are excited to foster our shared goal of bringing life changing therapeutics to patients with significant unmet needs. Join our conference call today, 8/31 at 8:30 a.m. ET to learn the details of the acquisition: https://bit.ly/47MqzQk Read the full announcement here: https://bit.ly/44FZTOE #WeAreZevra

Happy 4th of July from the Zevra team! 🎆 We wish everyone a joyful and relaxing holiday filled with great moments with friends and family. #StarsAndStripes #IndependenceDay

Zevra Therapeutics announced the appointment of Rahsaan Thompson as Chief Legal Officer, Secretary and Compliance Officer and Alison Peters as Chief People Officer. Mr. Thompson brings more than 25 years of experience as a business leader and attorney in the biotech industry and Ms. Peters brings more than 25 years of experience in human capital management developing high performing teams and leaders in the biotech industry. Learn more at https://bit.ly/3RPZw08

Zevra looks forward to attending the NATIONAL NIEMANN-PICK DISEASE FOUNDATION's Family Support and Medical Conference next week! At this annual event for the #NPC and #ASMD communities, our team will lead a Family Working Group session to gain insights from families affected by NPC on important topics facing the #raredisease community. #NNPDF

Hypersomnia Foundation is proud to celebrate 10 years of building a community that educates, empowers, and supports people who fight sleepiness.⁠ Here is Hypersomnia Foundation's board member, Veronica Moore, reflecting on HF's ten years of service. ⁠ Thank you for being on this journey with us. We are grateful to the sleep community, which continues to fiercely advocate for those with hypersomnia disorders. It is our honor to advocate alongside you.⁠ ⁠ #ThisIsIH #forthesleepyones #hypersomniaawareness #idiopathichypersomnia #sleepdisorder #FakeAwake

📢 Spread the word! Project Sleep cordially invites Members of Congress, staffers and interested stakeholders to attend "Awakening America: A Congressional Briefing on Sleep and Public Health" on Tuesday, July 16th, 2024 from 12:00pm - 12:45pm (Eastern) in the Rayburn House Office Building, Room 2075 in Washington, DC. ➡️ This event will cover new resources and tools now available to constituents nationwide. This briefing will also discuss gaps in early detection and diagnosis for the one in five Americans living with sleep disorders, along with legislative recommendations and updates on federal programs. ✨ Speakers Include: Dr. Michael Grandner, University of Arizona Dr. Kali Cyrus, Patient Advocate Julie Flygare, JD, President & CEO, Project Sleep 🏛️ Following the briefing, Project Sleep will invite Capitol staff to participate in a free educational sleep screening event to discuss concerns about their own sleep or wakefulness. Spread the word, learn more and RSVP: https://lnkd.in/gSQ8MvVw

Patient Worthy’s Jessica Lynn met with Daniel Gallo, PhD, our Senior Vice President of Medical Affairs and Advocacy, to discuss our first-in-class investigational therapeutic, #arimoclomol, and the unmet needs of the #NPC community. As the Prescription Drug User Fee Act action date for arimoclomol approaches in September, Gallo provides insights into how Zevra has remained patient-centric in our push to advance effective treatment. Full article can be found at https://bit.ly/3RJckFs

Did you know -- there are no approved treatments in the US for #NiemannPickDisease Type C? Our lead asset #arimoclomol has the potential to change that. Learn about our pipeline and follow our progress on the website and social channels. https://lnkd.in/eC89-re3 #NPC #NiemannPick

Just launched! Let’s hear from you! 🙌 Whoa, this is groundbreaking! What is the Patient Experience & Program Study? The first of its kind, it is a patient and supporter-led research project with oversight from a Community Advisory Committee. The goal to understand both met and unmet program needs as it relates to your experience. A third party consultant is leading this and all data will be anonymized. Why does this research matter? As people with Narcolepsy or Idiopathic Hypersomnia, you come from many different backgrounds. Your experience will be different from others. Your needs vary depending on where you are in your journey, your age, where you live, and your own unique circumstance. The findings and aggregated themes of the study will be reflected in a final Public Summary Report. What do we want to understand? We want to know how existing programs help you or what others might be offered to better serve you. Your opinions matter. Where are you in your journey with narcolepsy or idiopathic hypersomnia? What kinds of education, support, or advocacy programs help you? Are there other programs that are needed to best serve you? 💭 To participate, click here: https://ow.ly/RuZR50Sg8Wp ⭐ Thank you to our sponsors*: Avadel Pharmaceuticals, Harmony Biosciences, Jazz Pharmaceuticals, Takeda Pharmaceuticals, and Zevra Therapeutics. *Note: Sponsors are not involved in developing Study scope, format, or protocols, and will not have access to confidential data or patient information. #NarcolepsyNetwork #narcolepsy #idiopathichypersomnia #sleepdisorder #research #programs

Zevra Therapeutics today announced that Orsini is now the pharmacy partner for OLPRUVA® (sodium phenylbutyrate), a treatment for certain #UreaCycleDisorders. See full release for more information: https://prn.to/3XphPgp